...its neuroscience division fell 2% to $918 million. Excluding sales of ulcerative colitis drug Lialda mesalamine...

...two reported GI drugs accounting for 54% of those sales. Shire’s largest GI drug, Lialda mesalamine...
...sales of $569.4 million, down 28% from 2016 due to the launch of generic competitors. Lialda...

...cyclosporine ophthalmic emulsion. Other Allergan products facing loss-of-exclusivity headwinds in 2018 include gastrointestinal drug Delzicol mesalamine...
...disease drug Namenda XR memantine. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Ophthalmic Jaime De Leon Aczone Atrisone cyclosporine Dapsone topical gel Delzicol memantine mesalamine Namenda...

...cyclosporine ophthalmic emulsion. Other Allergan products facing loss-of-exclusivity headwinds in 2018 include gastrointestinal drug Delzicol mesalamine...

...PTAB) invalidated all claims in U.S. Patent 8,865,688 covering ulcerative colitis (UC) drug Apriso granulated mesalamine...
...Freiburg, Germany) (see BioCentury, March 23, 2009 & April 6, 2015 ). Apriso, which is mesalamine...

...PTO) upheld the validity of the only Orange Book-listed patent for ulcerative colitis drug Lialda mesalamine...
...and is owned by Cosmo’s Cosmo Technologies Ltd. subsidiary. Shire markets Lialda, which is 5-ASA mesalamine...
...NYSE:AGN, Dublin, Ireland) until the patent expires. Shire recorded $615 million in U.S. sales of Lialda...

...Office upheld the validity of the only Orange Book-listed patent for ulcerative colitis drug Lialda mesalamine...
...Cosmo Technologies Ltd. subsidiary of Cosmo Pharmaceuticals N.V (SIX:COPN). Shire markets Lialda, which is 5-ASA mesalamine...

...from Pernix [1] (A) Kerydin tavaborole from Anacor [3] Enbrel etanercept from Amgen [1] Lialda mesalamine...

...for the District of Southern Florida upheld a patent protecting Shire’s ulcerative colitis drug Lialda mesalamine...
...the patent expires on June 8, 2020. It is the only Orange Book-listed patent for Lialda...
...year. Shire recorded $684.4 million in worldwide sales of Lialda in 2015. The 5-aminosalicylate (5-ASA) mesalamine...

...The U.S. District Court of Southern Florida upheld a patent protecting ulcerative colitis drug Lialda mesalamine...
...NYSE:AGN) until the patent expires in 2020. It is the only Orange Book-listed patent for Lialda...
...case this year (see BioCentury Extra, Oct. 16, 2015) . Lialda is a 5-aminosalicylate (5-ASA) mesalamine...